Psoriasis

Immunology·MeSH: Psoriasis

Prevalence

3000.0 / 100K

Incidence

78.0 / 100K/yr

105 drugs in development·50 companies·31 clinical trials

Drug Pipeline by Phase

Approved(18)

Drug	Company
abrilada	PFIZER INC (PFE)
acitretin	Mylan II B.V. (MYL)
Brenzys (SB4)	Organon & Co. (OGN)
Compound Fluocinonide Tincture	China Health Industries Holdings, Inc. (CHHE)
Hadlima (SB5)	Organon & Co. (OGN)
Halcinonide Cream	China Health Industries Holdings, Inc. (CHHE)
imuldosa	Acorda Therapeutics, Inc. (ACOR)
Otrexup	Assertio Holdings, Inc. (ASRT)
psoria-light	WELLNESS CENTER USA, INC. (WCUI)
Renflexis (SB2)	Organon & Co. (OGN)
Taltz	ELI LILLY & Co (LLY)
Taltz®	ELI LILLY & Co (LLY)
Tremfya	Royalty Pharma plc (RPRX)
Triamcinolone Acetonide and Neomycin Paste	China Health Industries Holdings, Inc. (CHHE)
wezlana	AMGEN INC (AMGN)
yesintek	Bone Biologics Corp (BBLG)
ZORYVE (roflumilast) topical foam 0.3%	Arcutis Biotherapeutics, Inc. (ARQT)
ZORYVE foam (ARQ-151)	Arcutis Biotherapeutics, Inc. (ARQT)

Phase 3(39)

Drug	Company
300 mg imsidolimab	Vanda Pharmaceuticals Inc. (VNDA)
750 mg imsidolimab	Vanda Pharmaceuticals Inc. (VNDA)
adalimumab	GT Biopharma, Inc. (GTBP)
Adalimumab	AbbVie Inc. (ABBV)
bimekizumab	Cue Biopharma, Inc. (CUE)
blinded envudeucitinib	ALUMIS INC. (ALMS)
Blinded ESK-001	ALUMIS INC. (ALMS)
double-blind 200 mg imsidolimab	Vanda Pharmaceuticals Inc. (VNDA)
envudeucitinib	ALUMIS INC. (ALMS)
ESK-001	ALUMIS INC. (ALMS)
Etanercept	ENANTA PHARMACEUTICALS INC (ENTA)
Guselkumab	ENANTA PHARMACEUTICALS INC (ENTA)
ICP-488 Tablets	Crinetics Pharmaceuticals, Inc. (CRNX)
imsidolimab	Vanda Pharmaceuticals Inc. (VNDA)
imsidolimab 750 mg iv/200 mg sc	Vanda Pharmaceuticals Inc. (VNDA)
Ixekizumab	ELI LILLY & Co (LLY)
jnj-77242113	GH Research PLC (GHRS)
JNJ-77242113	ENANTA PHARMACEUTICALS INC (ENTA)
open-label 200 mg imsidolimab	Vanda Pharmaceuticals Inc. (VNDA)
open-label envudeucitinib	ALUMIS INC. (ALMS)
Open-Label ESK-001	ALUMIS INC. (ALMS)
piclidenoson	Can-Fite BioPharma Ltd. (CANF)
Roflumilast Foam 0.3%	Arcutis Biotherapeutics, Inc. (ARQT)
secukinumab	Novartis AG (NVS)
secukinumab	GT Biopharma, Inc. (GTBP)
sgx302	SOLIGENIX, INC. (SNGX)
sna-120	SIENNA BIOPHARMACEUTICALS, INC. (SNNA)
tak-279	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-279	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-279	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tildrakizumab	Teva Pharmaceutical Industries Limited (TEVA)
ustekinumab	POINT Biopharma Global Inc. (PNT)
ustekinumab	GT Biopharma, Inc. (GTBP)
Ustekinumab	ENANTA PHARMACEUTICALS INC (ENTA)
Ustekinumab	BRISTOL MYERS SQUIBB CO (BMY)
ustekinumab dose based on bsa	GH Research PLC (GHRS)
Vehicle cream	Organon & Co. (OGN)
Vehicle Foam	Arcutis Biotherapeutics, Inc. (ARQT)
XYNGARI™	Dermata Therapeutics Inc. (DRMA)

Phase 2(18)

Drug	Company
bimekizumab	POINT Biopharma Global Inc. (PNT)
bimekizumab	GT Biopharma, Inc. (GTBP)
dc-806	DICE Therapeutics, Inc. (DICE)
edp1815	Evelo Biosciences, Inc. (EVLO)
edp2939	Evelo Biosciences, Inc. (EVLO)
hs-10374	IMPACT BIOMEDICAL INC. (IBO)
hypericin	SOLIGENIX, INC. (SNGX)
JNJ-77242113	Crinetics Pharmaceuticals, Inc. (CRNX)
orka-001 induction dose	Oruka Therapeutics, Inc. (ORKA)
orka-001 maintenance dose	Oruka Therapeutics, Inc. (ORKA)
orka-003	Oruka Therapeutics, Inc. (ORKA)
orka-021	Oruka Therapeutics, Inc. (ORKA)
rap103 200mg bid	GT Biopharma, Inc. (GTBP)
rap103 400mg single dose	GT Biopharma, Inc. (GTBP)
sar441566	Sanofi (SNY)
SAR441566	Sanofi (SNY)
tapinarof cream, 1%	Organon & Co. (OGN)
tqh3906	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)

Phase 1(6)

Drug	Company
ARQ-154 Foam 0.3%	Arcutis Biotherapeutics, Inc. (ARQT)
ly4100511	ELI LILLY & Co (LLY)
orka-001	Oruka Therapeutics, Inc. (ORKA)
orka-002	Oruka Therapeutics, Inc. (ORKA)
PN-881	Protagonist Therapeutics, Inc (PTGX)
vyn202	VYNE Therapeutics Inc. (VYNE)

Preclinical(8)

Drug	Company
adi-100	Aditxt, Inc. (ADTX)
atopidine	NEUROPATHIX, INC. (TYGS)
ht-003	Hoth Therapeutics, Inc. (HOTH)
KT-294	Kymera Therapeutics, Inc. (KYMR)
KT-295	Kymera Therapeutics, Inc. (KYMR)
leaô	NEUROPATHIX, INC. (TYGS)
nanocyclo	IMMUNE PHARMACEUTICALS INC (IMNP)
phoenix auto	Phoenix Life Sciences International Limited. (PLSI)

Unknown(1)

Drug	Company
Biologic or targeted synthetic DMARD	UNITED THERAPEUTICS Corp (UTHR)

BLA Filed(3)

Drug	Company
Icotyde	Protagonist Therapeutics, Inc (PTGX)
imsidolimab	ANAPTYSBIO, INC (ANAB)
m923	MOMENTA PHARMACEUTICALS INC (MNTA)

Phase 1/Phase 2(1)

Drug	Company
XmAb564	Xencor Inc (XNCR)

Phase 4(11)

Drug	Company
Deucravacitinib	BRISTOL MYERS SQUIBB CO (BMY)
Deucravacitinib	AbbVie Inc. (ABBV)
idp-118 lotion	Bausch Health Companies Inc. (BHC)
Risankizumab	AbbVie Inc. (ABBV)
secikinumab	Novartis AG (NVS)
Secikinumab	Novartis AG (NVS)
Tapinarof	Organon & Co. (OGN)
Tirzepatide	ELI LILLY & Co (LLY)
Triamcinolone	Clearside Biomedical, Inc. (CLSDQ)
ustekinumab	GH Research PLC (GHRS)
vtama	Organon & Co. (OGN)

Compare drugs

abrilada vs acitretin abrilada vs Brenzys (SB4)abrilada vs Compound Fluocinonide Tincture

Frequently asked questions

How many drugs are in development for Psoriasis?

BioSniper tracks 105 drugs in development for Psoriasis across 50 companies.

How many clinical trials target Psoriasis?

There are 31 clinical trials targeting Psoriasis tracked by BioSniper.

What is the prevalence of Psoriasis?

The estimated prevalence of Psoriasis is approximately 3000.0 per 100,000 population.

Deep-dive into Psoriasis

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis